Links are not yet activated.
To activate, add a link back to submitpr.org from your website and contact @jaycosta on Telegram,
or pay via Solana (from $19.95) for instant activation.
Moderna's experimental mRNA flu vaccine cleared a critical regulatory obstacle in February after the U.S. Food and Drug Administration reversed an earlier refusal to review the company's application, setting up a decision that could reshape how Americans protect themselves against seasonal influenza.The FDA has set August 5, 2026, as the target date to rule on mRNA-1010, Moderna's first non-COVID vaccine candidate. If approved, the shot would be available for the 2026-2027 flu season and mark the first time mRNA technology has been applied to influenza prevention at commercial scale.
Flu vaccines have relied on the same egg-based manufacturing process since the 1940s. Production takes six months or longer, and the virus frequently mutates during that window, leaving patients with shots that match poorly against the strains actually circulating. Efficacy in any given season hovers between 40 and 60 percent.
mRNA technology sidesteps this problem. Vaccines can be formulated in weeks rather than months, allowing manufacturers to lock in strain selection much closer to flu season. Moderna has spent four years and roughly $750 million in financing from Blackstone Life Sciences to bring mRNA-1010 through clinical development.
The path has not been smooth. An early Phase 3 study in 2023 showed strong results against influenza A strains but missed its target for influenza B, forcing Moderna to reformulate and run a new trial.
The pivotal Phase 3 study, designated P304, enrolled 40,805 adults aged 50 and older across 11 countries. Results released on June 30, 2025, showed mRNA-1010 achieved 26.6 percent higher relative vaccine efficacy compared to a licensed standard-dose flu shot.
Breaking that down by strain: the vaccine delivered 29.6 percent better protection against A/H1N1, 22.2 percent against A/H3N2, and 29.1 percent against B/Victoria. Among adults 65 and older, overall relative efficacy was 27.4 percent.
Those numbers may sound modest in isolation. In context, they represent one of the largest efficacy gains over existing flu vaccines demonstrated in a late-stage trial. Standard flu shots prevent an estimated 100,000 hospitalizations annually in the United States. A 27 percent improvement over that baseline would translate to tens of thousands of additional prevented cases each year.
The regulatory timeline took an unexpected turn. Moderna submitted its Biologics License Application in late 2025. On February 12, 2026, the FDA issued a Refusal-to-File letter. Vinay Prasad, the agency's top vaccine official, signed the rejection. The stated reason: Moderna had compared mRNA-1010 to a standard-dose vaccine rather than a high-dose formulation like Sanofi's Fluzone HD for the 65-and-older population.
Moderna pushed back. Six days later, on February 18, the company emerged from what the industry calls a Type A meeting with a revised path forward. The FDA agreed to review the application under a split strategy: full approval for adults 50 to 64, and accelerated approval for those 65 and older with post-marketing study requirements.
For full coverage, visit https://www.linos.ai/health/moderna-mrna-flu-vaccine-fda-review/
About Linos NEWS: Linos NEWS (https://www.linos.ai) delivers breaking news and in-depth analysis across politics, technology, business, science, health, world affairs, sports, and entertainment.